Two new class 1 drugs of Haisco have entered the new field and new indications of innovative drugs in anesthesia are here

On February 8th, the good news of Hisco's innovative drugs continued: Class 1 new drugs HSK31858 tablets and HSK31679 tablets were approved for clinical use, and the new drug clinical application for HSK36212 capsules was also undertaken by CDE; in addition, the company's cyclopofol injection, which was approved for marketing in 2020 The listing application for the sixth indication of the liquid has also been accepted.

Table 1: Hisco's Class 1 new drugs for clinical application in 2021

Source: CDE official website, Minet database

In 2021, Hisco has submitted a total of 5 clinical applications for Class 1 new drugs, all of which have been approved for clinical use so far

HSK29116 powder is an oral Protac small molecule anti-tumor drug.

The HSK31679 tablets and HSK31858 tablets approved for clinical use this time are both products declared for the first time

Figure 1: Hisco's latest clinical application of Class 1 new drugs

Source: CDE official website

In January 2022, Haisco submitted a new drug clinical application for HSK36273 for injection, which is currently under review and approval.

Table 2: Reported production situation of Haisco Cyclopofol Injection

Source: MED2.

On February 8, Haisco issued an announcement stating that the application for listing of Cyclopofol Injection for the indication of "sedation and anesthesia for gynecological outpatient surgery" has been accepted

Judging from the current situation, Haisco's innovative drugs maintain a positive trend of "approval and application" every year.